Biomarkers for outcome upon MAPK inhibition in melanoma

Affiliations

¹ Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands. Electronic address: c.blank@nki.nl.

Comment

Christian Blank. Lancet Oncol. 2016 Dec.

. 2016 Dec;17(12):1634-1636.

doi: 10.1016/S1470-2045(16)30593-9.

¹ Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands. Electronic address: c.blank@nki.nl.

No abstract available

Comment on

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Long GV, et al. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16. Lancet Oncol. 2016. PMID: 27864013